Even if there is considerable heterogeneity in the level of CD8+ T cells and an incomplete understanding of the immune checkpoint targets expressed in neurofibroma and MPNST [72,73], clinical trials are actively running (e.g., EUCTR-2015-004747-39, NCT02691026) and show promising results [74]. Here, CD8A is linked to malignant peripheral nerve sheath tumor.